Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development
Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan
Xentria’s bid to find a new use for TNF inhibitors has landed it with $45 million in the bank. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal Pharmaceuticals to hand over the upfront payment and offer more than $600 million in potential future paydays for North American rights to its candidate.
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, Illinois today announced it has joined The Association for Accessible Medicines (AAM), the trade association representing the generics and biosimilars industry. AAM works to ensure more accessibility to generic and biosimilar medicines, and to advance policies that promote sustainability of the accessible medicines industry.
Enforcement Report - Week of September 22, 2021
Meitheal Pharmaceuticals has reported data from a research partnership with Premier Applied Sciences, where prophylactic treatment with anticoagulants offered enhanced clinical outcomes in hospitalised Covid-19 patients.
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company based in Chicago, Illinois, today announced findings from a research collaboration with Premier Applied Sciences (PAS), the research and analytics division of Premier Inc., evaluating anticoagulant treatment on outcomes of hospitalized patients diagnosed with COVID-19. Anticoagulants are medications that prevent blood clots. Research has shown that patients with COVID-19 are more prone to developing blood clots during the course of their illness.
Enforcement Report - Week of March 3, 2021